Business
Bellus Health to Present at Bloom Burton & Co. Healthcare Investor Conference
LAVAL, QC, June 6, 2012 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Comp...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\n\n\nLAVAL, QC, June 6, 2012 /CNW/ - BELLUS Health Inc. (TSX: BLU) (\"BELLUS\n Health\" or the \"Company\") today advised that Roberto Bellini, President\n and Chief Executive Officer, will present at the 2012 Bloom Burton &\n Co. Healthcare Investor Conference. The presentation will take place at\n 4:00 pm Eastern Time on Thursday, June 21st, 2012. The conference is being held at the Toronto Board of Trade in\n Toronto, Ontario.\n\n\nThe Bloom Burton & Co. Healthcare Investor Conference brings together\n U.S., Canadian and European investors who are interested in the latest\n developments in the Canadian healthcare sector. Attendees will have an\n opportunity to obtain corporate updates from the premier Canadian\n public and private companies through presentations and break-out Q&A\n sessions.\n\n\nAbout BELLUS Health (www.bellushealth.com)\n\n\nBELLUS Health is a development-focused healthcare company concentrating\n on products that provide innovative health solutions and address\n critical unmet medical needs. The Company, in collaboration with its\n partner, Celtic Therapeutics Inc., is currently advancing its novel\n drug candidate KIACTA™, through a Phase III trial for the treatment of\n AA amyloidosis, an orphan indication resulting in renal dysfunction\n that often rapidly leads to dialysis and eventually death. AA\n amyloidosis affects approximately 50,000 individuals in the United\n States, Europe and Japan.\n\n\n Jonathan Ross TMX Equicom 416-815-0700 ext. 248 | [email protected] \n","length":1794,"tagName":"div"}]